Overview of Uroflo

Property	Description
Active Ingredient	Terazosin monohydrochloride dihydrate
Form	Oral Capsule
Pharmacological Class	Alpha-Adrenergic Blocker (α1-blocker)
General Purpose	Reduction of vascular resistance, improvement of urinary flow
Origin	Synthetic, Quinazoline Derivative

Uroflo is a prescription medicine containing the single active substance Terazosin, classified as an alpha-adrenergic blocker (α1-blocker) used primarily to influence the body’s vascular and urinary systems. Terazosin is a synthetic compound, chemically categorized as a quinazoline derivative, typically presented as an oral capsule.

The Chemical Identity and Class of Terazosin

Uroflo is the commercial term for the generic entity terazosin monohydrochloride dihydrate. This agent is classified as an α1-selective adrenoceptor blocking agent. This designation signifies that the drug's action is highly specific, selectively interfering with signals sent by adrenaline-like substances to target alpha-1 receptors.

The quinazoline derivative structure of Terazosin is chemically distinct and is clinically recognized for providing this targeted inhibition. Terazosin is an oral medication with established antihypertensive activity. This profile indicates the drug’s fundamental purpose is to oppose natural signaling processes that cause smooth muscle contraction in the circulatory system.

Uroflo's Fundamental Action and General Purpose

The core mechanism of this alpha-blocker is to induce smooth muscle relaxation and resultant vasodilation (vessel widening). This physiological effect occurs by blocking the α₁ receptors on the smooth muscles in blood vessel walls and in the lower urinary tract, particularly the prostate and the neck of the bladder.

The general therapeutic utility of Uroflo is defined by this dual effect: it helps to reduce high systemic resistance in the circulatory system, which can contribute to easing strain on the heart, and it helps to improve obstructed urinary flow by alleviating constriction. This comprehensive physiological action defines the core benefit of the Terazosin compound.

What side effects are possible with Uroflo?

Possible Side Effects and Safety Information

The safety profile of Uroflo (Terazosin), an alpha-adrenergic blocker, is characterized by effects primarily related to the vascular system and categorized by frequency of occurrence, as documented in official regulatory labeling.

Frequency-Classified Adverse Reactions

The most commonly documented adverse reactions, classified as Common in regulatory sources, include Dizziness, Headache, Fatigue (Asthenia), Somnolence (drowsiness), Nasal Congestion, and Peripheral Oedema (swelling of extremities). Postural Hypotension—the drop in blood pressure when standing up—is also a common, expected effect related to the drug's mechanism.

Reactions categorized as Uncommon include Syncope (fainting), which is documented as a clinically important reaction, and Palpitations. The prolonged, painful erection known as Priapism is listed as a Rare adverse reaction.

System-Organ Class	Common Adverse Reactions
Vascular Disorders	Postural Hypotension
Nervous System Disorders	Dizziness, Headache, Somnolence
General Disorders	Fatigue (Asthenia), Peripheral Oedema
Respiratory Disorders	Nasal Congestion

Serious Safety Patterns and Constraints

The highest risk of Postural Hypotension and Syncope is documented as occurring at the initiation of treatment (the first-dose effect) or when the dosage is increased. This pattern establishes the most significant safety consideration related to exposure timing.

Safety-related restrictions include a contraindication for individuals with a known history of Syncope upon micturition or a hypersensitivity to Terazosin or other quinazoline derivatives. Additionally, the label notes a risk of Intraoperative Floppy Iris Syndrome (IFIS), a complication for patients taking or previously treated with this class of medicine who undergo cataract surgery. Official safety notes also require caution for use in older adults due to increased susceptibility to hypotensive events and in patients with severe hepatic impairment.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Uroflo (terazosin) is officially documented as resulting in an excessive hypotensive response, meaning a severe drop in blood pressure. This alpha-1 blockade effect defines the official overdose profile and dictates the required emergency action.

Documented Clinical Manifestations: The primary manifestations listed in regulatory documents include acute hypotension, extreme dizziness, and lightheadedness. These can progress to the most severe orthostatic effects: syncope (fainting) or palpitations.

When to Seek Immediate Medical Help: Immediate medical attention is mandated upon a known or suspected overdose, even if initial symptoms are absent. Contact emergency services (911) immediately if the individual shows signs of life-threatening systemic manifestations, including collapse, seizures, trouble breathing, or the inability to be awakened. Otherwise, calling the Poison Help line is the required action as described in official documents.

Officially Described Supportive Measures: There is no specific chemical antidote known for Terazosin toxicity. Management is strictly symptomatic and supportive, focusing on the restoration of cardiovascular stability. This includes placing the patient in a recumbent position to help restore blood pressure. For cases involving persistent shock or hemodynamic instability, official guidance outlines the need for volume expanders and, if necessary, the use of vasopressors to support blood pressure parameters. Monitoring of renal function is also a documented procedural step.

Therapeutic Uses of Uroflo

What Uroflo Treats: Main Uses and Benefits

Uroflo is commonly used to help manage symptoms related to two major therapeutic domains: symptomatic Benign Prostatic Hyperplasia (BPH) and Essential Hypertension. This medication is indicated to both treat the uncomfortable symptoms of an enlarged prostate and manage high blood pressure.

This medication is often used during phases when symptoms become more noticeable for chronic conditions, including conditions presenting with systemic or localized discomfort. The primary indications addressed are Hypertension and BPH, a condition characterized by periods of heightened symptoms.

Relief for Symptoms of Benign Prostatic Hyperplasia (BPH)

This application is used in situations involving certain distressing urinary symptoms that interfere with daily functioning, primarily in adult men. Uroflo may assist in easing difficulty starting urination (hesitancy), and is relevant for managing the weak or intermittent stream, and the disruptive symptom of nocturia (frequent nighttime urges). This provides support that helps ease the overall symptom burden and contributes to improved comfort during symptomatic periods.

Management of Essential Hypertension

Uroflo is applied across domains where additional symptomatic support is needed to control high blood pressure. It is commonly used to help with symptoms related to systemic imbalance for high blood pressure. This use is relevant when supportive symptom management is appropriate, assisting with maintaining functional stability and may be part of symptomatic management for this chronic condition.

Quick Fact: Relief for Symptomatic Urinary Difficulty Uroflo is commonly used to help address BPH by supporting the easing of symptoms related to physical discomfort and the related nocturia, which is relevant for managing symptoms that interfere with daily comfort.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Regulatory Eligibility Profile

Uroflo (Tamsulosin) is approved for use in adult males only. Its eligibility profile is strictly defined by contraindications, sex, age, and organ function status as outlined in official regulatory documents (e.g., FDA, EMA).

Classification	Who Must Not Use Uroflo	Restriction Details
Absolute Contraindication	Individuals with known hypersensitivity (including angioedema) to tamsulosin or a history of orthostatic hypotension (a form of low blood pressure upon standing).	Also contraindicated with some strong CYP3A4 inhibitors and other alpha-blockers.
Sex/Age Exclusion	Women (pregnant or not) and the pediatric population (under 18 years).	Safety and efficacy have not been established in these groups; the drug is not indicated for them.
Organ Impairment	Patients with severe hepatic insufficiency (severe liver impairment).	Caution is warranted for patients with severe renal impairment (creatinine clearance <10 mL/min) as they have not been studied.
Conditional Use	Patients scheduled for cataract or glaucoma surgery.	Initiation of therapy is not recommended due to the risk of Intraoperative Floppy Iris Syndrome (IFIS).

All patients must be screened for contraindications prior to treatment initiation. Eligibility is solely determined by these regulatory-mandated restrictions and exclusions.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Uroflo is extensively metabolized, and its interaction profile is governed by two main constraints: metabolic inhibition and additive pharmacodynamic effects.

Interaction Classification	Relevant Substances/Classes
Contraindicated	Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir)
Not Recommended	Other Alpha-Blockers; Strong P-glycoprotein (P-gp) Inhibitors (e.g., cyclosporine)
Use with Caution	PDE5 Inhibitors (e.g., sildenafil); Antihypertensive Agents

Co-administration with strong CYP3A4 inhibitors is officially contraindicated due to the potential for a significant increase (e.g., approximately 3.2-fold increase in exposure) of Uroflo's plasma concentrations. This pharmacokinetic risk is also a factor when considering strong P-gp inhibitors, which are generally not recommended due to Uroflo being a P-gp substrate.

Pharmacodynamic interactions are relevant with other agents that lower blood pressure, such as antihypertensive agents and PDE5 inhibitors, requiring clinical caution due to the risk of additive hypotensive effects. Concomitant use with other alpha-blockers is also not recommended due to expected additive effects.

Additionally, the regulatory documents specify that Uroflo is contraindicated in patients with severe renal impairment and severe hepatic impairment. In patients with moderate renal impairment, the required dosage adjustment is directly linked to an observed three-fold increase in systemic drug exposure. Uroflo is instructed to be taken with a meal as an official procedural constraint to minimize the risk of interaction-related orthostatic events.

Mechanism of Action

Uroflo's mechanism of action involves highly selective antagonism of the alpha1A-adrenergic receptor subtype. This receptor subtype is the predominant alpha1-adrenoceptor expressed in the prostatic stroma, prostatic capsule, and bladder neck smooth muscle tissues. Under normal conditions, the activation of alpha1A-adrenergic receptors by endogenous catecholamines, such as norepinephrine, triggers a Gq-coupled protein signaling cascade. This cascade ultimately leads to the generation of inositol triphosphate (IP3) and diacylglycerol (DAG), causing a subsequent increase in intracellular calcium ( Ca^2+) concentration and smooth muscle contraction. Uroflo competitively binds to the alpha1A-adrenergic receptor, preventing norepinephrine from initiating the signaling pathway. The resulting blockade leads to a cessation of the Ca^2+ mobilization and subsequent relaxation of the smooth muscle within the lower urinary tract. The system-level physiological consequence is a reduction in prostatic urethral resistance and an increase in urinary flow dynamics.

Dosage and Administration Information

How Uroflo Is Used

Uroflo (terazosin) is administered strictly via the oral route and is available in strengths such as 1 mg, 2 mg, 5 mg, and 10 mg. The usage principles involve a cautious initiation followed by a stepwise titration, which is critical for establishing the long-term regimen for conditions like Benign Prostatic Hyperplasia (BPH) and Hypertension.

Official Dosing and Administration

Feature	Instruction
Route of Administration	Oral (swallowed).
Initial Dose	1 mg once daily for both approved indications.
Timing of Initial Dose	The first 1 mg dose must be taken at bedtime for all patients.
With/Without Food	May be taken with or without food.

Titration and Maintenance Principles

Therapy is initiated with the 1 mg dose, which is then gradually increased, typically in a stepwise fashion (e.g., 1 mg to 2 mg to 5 mg), at intervals of one to two weeks.

The most common frequency for Uroflo is once daily. For BPH, the maintenance dose commonly ranges from 2 mg to 10 mg, with 10 mg being the dose generally required to assess a response. The maximum daily dose supported by clinical data for both BPH and Hypertension is 20 mg.

Procedural and Population Constraints

If administration is interrupted for several days or more, the protocol requires that therapy must be re-instituted at the initial 1 mg dose. Regarding specific populations, the medication is not recommended for use in children because efficacy and safety have not been established. Patients with severe hepatic impairment should exercise particular caution during titration, as its use is not recommended in this group.

This structured approach defines the standardized sequence for dose management and administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Uroflo

Studies Related to Symptomatic Benign Prostatic Hyperplasia (BPH)

The evidence base for Uroflo in the context of BPH consists mainly of Randomized Controlled Trials (RCTs) and systematic reviews. These trials often compared the administration of Uroflo to a placebo, with research exploring how symptoms change over time following the administration of Uroflo in adult men with moderate-to-severe lower urinary tract symptoms associated with BPH. Studies generally focused on two types of outcomes: subjective symptom change (using standardized questionnaires) and objective functional measures (including changes in peak urinary flow rate, Qmax). Measurements of change in objective measures, such as flow rates, varied across several trials, and research highlights changes measured during the study period. What remains unclear involves the long-term impact on the progression of BPH, as follow-up durations were limited in the pivotal efficacy trials.

Studies Related to Essential Hypertension (High Blood Pressure)

Research exploring Uroflo for high blood pressure was evaluated in RCTs, where the goal was to study changes in blood pressure measurements, either alone or in combination with other agents. These studies focused on outcomes related to systemic imbalance, specifically monitoring the change in standing and supine systolic and diastolic blood pressure measurements. Studies reported how blood pressure measurements evolved in the observed populations, and data described patterns related to changes in these measurements during the study period. When comparing this class of medication to certain other primary classes of antihypertensive agents, findings from some major long-term trials reported variations in the occurrence of long-term cardiovascular outcomes, including heart failure.

Concurrent Evaluation of BPH and Hypertension

Research has also explored the concurrent evaluation of two health conditions in men presenting with both symptomatic BPH and essential hypertension. Dedicated short-term RCTs were conducted to evaluate both blood pressure measurements and BPH symptoms concurrently. Studies monitored simultaneous patterns in both blood pressure measurements and the documentation of BPH symptom scores, with evidence derived from settings with varying symptom burdens. What remains uncertain is the need for more research exploring the long-term impact of this combined management approach on the chronic progression of both BPH and hypertension over an extended period.

Key Studies & References Terazosin Information - NIH MedlinePlus overview

Frequently Asked Questions (FAQ)

Common questions about Uroflo (FAQ)

Q: Does Uroflo affect the liver or kidney function?

A: Official information indicates that Uroflo is primarily metabolized by the liver. Regarding kidney function, regulatory data suggests that no specific dosage adjustment for renal impairment is typically required. Studies have noted a low rate of temporary elevations in liver enzymes, which was comparable to patients taking an inactive substance (placebo).

Q: What should be done if an allergic reaction is suspected after taking Uroflo?

A: The official product label notes that a severe allergic reaction, such as anaphylaxis, is a potential risk associated with this medication. If signs of an allergic reaction—including difficulty breathing, or swelling of the face, lips, tongue, or throat—official instructions state that immediate emergency medical attention is needed.

Q: Does Uroflo interact with common pain relievers like ibuprofen?

A: Regulatory guidance focuses on interactions with other blood pressure-lowering agents. However, patients taking Uroflo for high blood pressure are generally advised to discuss all nonprescription products, including pain relievers, with their healthcare provider, due to the potential for certain over-the-counter medications to affect blood pressure.

Q: Is Uroflo suitable for people with diabetes?

A: The official European regulatory guidance notes that special care should be taken when Uroflo is administered to individuals suffering from insulin-dependent diabetes. The determination of the drug’s appropriateness is made by a healthcare provider.

Q: Are there specific warnings about Uroflo for people with heart problems?

A: Official product information advises caution for individuals with pre-existing ischemic or other heart diseases. Warnings specifically address the risk in patients with left ventricular failure, noting that the drug’s mechanism of action may result in a drop in blood pressure and cardiac output in certain individuals in this group.

Q: How quickly can someone expect Uroflo to start working?

A: In clinical studies, a decrease in blood pressure was observed relatively quickly following the first oral dose. For BPH symptoms, statistically significant improvements have been observed starting around the second week of treatment and continuing throughout the duration of the studies.

Q: Is Uroflo safe to take for long periods of time?

A: Studies indicate that symptomatic improvement in BPH has been maintained for at least two years of continuous therapy in some patients. While data is available on symptom maintenance, the available efficacy trials had limited follow-up duration regarding the drug’s impact on the long-term progression of the condition.

Q: What effect does Uroflo have on blood pressure?

A: Uroflo is an alpha-blocker that acts to reduce high systemic resistance, and its use is associated with a decrease in blood pressure. In clinical trials, the documented reduction in blood pressure compared to placebo typically falls within a specific range for both systolic and diastolic measurements.

Q: Is Uroflo recommended for older patients?

A: Official regulatory documents require that particular caution be used when prescribing Uroflo to older adults (65 years and over). This is because advanced age is associated with an increased susceptibility to the hypotensive effects of the drug, such as postural hypotension (a drop in blood pressure upon standing).

Q: Are there restrictions on driving or operating machinery while taking Uroflo?

A: Official documents state that performing hazardous tasks, including driving, should be avoided for 12 hours after the initial dose, following any subsequent dosage increase, or after re-instituting therapy. This caution is due to the potential for dizziness or drowsiness associated with the medication.

Q: Is Uroflo a habit-forming or addictive medicine?

A: No, Uroflo is not classified as a controlled substance under the U.S. Controlled Substances Act (CSA). The drug is not listed as a habit-forming or addictive medicine in regulatory documents.

Q: Does Uroflo affect fertility or reproductive health?

A: Official labeling notes potential side effects involving the genitourinary system, including impotence and priapism. Priapism is described as a painful, prolonged erection documented as requiring immediate medical attention.

Q: Will Uroflo completely cure the underlying medical condition?

A: Regulatory information indicates that Uroflo is intended to help relieve the symptoms of Benign Prostatic Hyperplasia (BPH). It does not, however, cause a reduction in the size of the prostate gland itself, and its use may not prevent the potential need for surgery in the future.

Q: What is the recommended duration of treatment with Uroflo?

A: The overall length of therapy is determined by the prescribing healthcare professional. Official documents note that treatment may need to be continued for a minimum of 4 to 6 weeks at the maintenance dose to fully determine whether the medication has provided a beneficial response.

Q: What happens when Uroflo treatment is stopped?

A: If treatment is discontinued for several days or longer, official protocol dictates that therapy should be re-instituted using the initial, cautious dosing regimen to reduce the risk of hypotensive events.

Q: Is it normal to experience a change in sleep patterns while on Uroflo?

A: Official documents list somnolence (drowsiness) as a common adverse reaction associated with Uroflo. Additionally, insomnia (difficulty sleeping) has been noted as an infrequent reaction in postmarketing safety reports.

Q: What if Uroflo does not seem to be working after a few weeks?

A: Regulatory documents indicate that patients should expect to notice an effect on their BPH symptoms within 2 to 4 weeks of starting the medication. The drug’s expected time window to assess benefit is up to four to six weeks, as noted in regulatory documents.

Q: Are there studies comparing Uroflo to a placebo?

A: Yes, the evidence base supporting the use of Uroflo includes randomized, controlled clinical studies where the effects of the medication were compared to those of a placebo (an inactive substance). These studies compared outcomes like symptom evaluation and objective flow rate measurements.

Q: Can Uroflo be purchased without a prescription in some places?

A: No, Uroflo is classified by regulatory authorities as a prescription-only medication (Rx). It must be obtained with a prescription from a licensed healthcare provider.

Q: What research themes are commonly studied regarding Uroflo?

A: Common research themes include the measurement of subjective change in BPH symptoms using standardized questionnaires and objective functional measures, such as peak urinary flow rate. Studies also consistently monitor changes in both standing and supine blood pressure measurements.

Q: Are there lifestyle changes that help Uroflo work better?

A: Regulatory documents mention that certain activities and conditions, such as long periods of standing, increased physical activity, warm weather, and consuming alcoholic beverages, can potentially increase the risk of hypotensive effects.

Q: Can Uroflo be taken with vitamins or supplements?

A: Regulatory guidance notes a caution regarding nonprescription products. Due to the potential for some over-the-counter medicines or supplements to affect blood pressure, these should be discussed with a healthcare provider.

Q: Are there generic versions of Uroflo available?

A: Yes, Uroflo is the brand name for the active ingredient terazosin hydrochloride. The generic formulation of terazosin is available from several different manufacturers.

How should Uroflo be stored and disposed of?

How to Store and Dispose of Uroflo (Terazosin Hydrochloride)

The storage and disposal of Uroflo capsules must strictly adhere to officially labeled requirements to ensure product stability.

Required Storage Conditions

Requirement	Official Regulatory Statement
Temperature Range	Store between 15 C and 30 C (59°F and 86°F), precluding freezing or refrigeration.
Protection	Must be protected from light and moisture.
Container	Keep the container tightly closed and store in a tight, light-resistant container.

Safety and Disposal

Uroflo capsules must be kept out of the reach of children, often requiring a child-resistant closure on the dispensed container. For disposal, unused or expired medicine should be discarded according to local regulations for pharmaceutical waste; official labeling notes no special hazardous waste requirements.

Uroflo